Promoting Maternal and Infant Survival Everywhere (PROMISE)

Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID)
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Protocol Summary: 1077BF is a research protocol designed to address in an integrated and comprehensive fashion three critical questions currently facing HIV-infected pregnancy and postpartum women and their infants:

  1. What is the optimal intervention for the prevention of antipartum and intrapartum transmission of HIV?
  2. What is the optimal intervention for the prevention of postpartum transmission in breastfeeding (BF) infants?
  3. What is the optimal intervention for the preservation of maternal health after the risk period for prevention of mother-to-child transmission ends (either at delivery or cessation of BF)?

PROMISE seeks to examine effective methods of preventing transmission of HIV from mother-to-child during pregnancy, labor and delivery, and breastfeeding.  This is one component of the three-part PROMISE study that is being conducted at various sites in Africa and other parts of the world where women typically receive a short course of HAART during pregnancy and where breastfeeding is common.

Years:  2011 – present

Investigator:  Tsungai Chipato, MBChB, FRCOG, MCE

Locations:  Parirenyatwa, Seke North, and St. Mary’s CRSs


Completed Study


Fowler MG, Qin M, Fiscus SA, Currier JS, et al (2016) Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med. 2016 Nov 3;375(18):1726-1737.

Comments are closed.